| Cancer Biology and Pharmacology (Master) (with Thesis) | |||||
| Master | TR-NQF-HE: Level 7 | QF-EHEA: Second Cycle | EQF-LLL: Level 7 | ||
| Course Code: | KBY5012 | ||||
| Course Name: | Tumor Heterogeneity and Drug Resistance | ||||
| Semester: | Spring | ||||
| Course Credits: |
|
||||
| Language of instruction: | Turkish | ||||
| Course Condition: | |||||
| Does the Course Require Work Experience?: | No | ||||
| Type of course: | Departmental Elective | ||||
| Course Level: |
|
||||
| Mode of Delivery: | Face to face | ||||
| Course Coordinator: | Dr. Öğr. Üy. ÖYKÜ GÖNÜL GEYİK | ||||
| Course Lecturer(s): | Öykü GÖNÜL GEYİK, Huri BULUT | ||||
| Course Assistants: |
| Course Objectives: | The aim of this course; to teach students the molecular and genetic causes of tumor heterogeneity and to enable them to comprehend the mechanisms of cancer drug resistance. |
| Course Content: | Molecular and genetic mechanisms of tumoral heterogeneity in cancer and cancer drug resistance that develops in parallel with it. |
|
The students who have succeeded in this course;
1) Explain the importance of heterogeneity arising from clones playing a role in cancer development and list the reasons for the emergence of these clones. 2) Explains the reflection of Darwinian evolution on a clone basis. 3) Count the effects of genomic instability on the development of clones causing cancer heterogeneity. 4) Explain the effects of specific gene expression patterns observed in clones on phenotype. 5) Discusses the heterogeneous progression of accumulated genetic changes in tumors growing monoclonally. 6) Explain the effect of intra-tumor clonal heterogeneity on carcinogenesis processes such as invasion, metastasis, and angiogenesis. 7) Discusses cancer microenvironment and immunology in terms of intra-tumor heterogeneity. 8) Discusses cancer stem cell and tumor dormancy in terms of tumoral heterogeneity. 9) Discusses the effects of DNA repair mechanisms and changes in molecules involved in genome integrity on resistance to cancer drugs. 10) Explain the effects of changes in epigenetic regulation in cancer on cancer drug resistance. 11) Explain the effects of defects in the elements involved in cellular energetic mechanisms on the development of cancer drug resistance. 12) Discusses the effects of deregulations related to proliferation and cell death signaling mechanisms on the development of drug resistance. 13) Explain the effects of processes associated with replicative immortality on cancer drug resistance. 14) Discusses drug development strategies for targeting tumor clones. 15) Evaluates and discusses current scientific publications on intra-tumor clonal heterogeneity and its effect on drug resistance. 16) Discusses the importance of cancer drug resistance and tumoral heterogeneity studies in cancer research and the development of personalized medicine. |
| Week | Subject | Related Preparation |
| 1) | Intratumour heterogeneity resulting from clones involved in cancer progression | |
| 2) | The role of monoclonal carcinogenesis and Darwinian evolution in the development of subclones | |
| 3) | Effects of genomic instability on the development of clones causing cancer heterogeneity | |
| 4) | Effects of specific gene expression patterns observed in clones on phenotype | |
| 5) | The effect of intra-tumor clonal heterogeneity on carcinogenesis processes such as invasion, metastasis, and angiogenesis | |
| 6) | The importance of cancer microenvironment and immunology and inflammatory processes in terms of intra-tumor heterogeneity | |
| 7) | Examination of cancer stem cells and tumor dormancy in terms of tumoral heterogeneity | |
| 8) | The effects of changes in molecules involved in DNA repair mechanisms and genome integrity on resistance to cancer drugs | |
| 9) | The effects of changes in epigenetic regulation in cancer on cancer drug resistance | |
| 10) | Development of cancer drug resistance as a result of defects in the elements involved in cellular energetic mechanisms | |
| 11) | The effects of deregulations on proliferation and cell death signaling mechanisms on the development of drug resistance | |
| 12) | Effects of processes associated with replicative immortality on cancer drug resistance | |
| 13) | The effect of intra-tumor clonal heterogeneity on drug resistance and drug development strategies for targeting tumor clones | |
| 14) | The role of cancer drug resistance and tumoral heterogeneity studies in cancer research and their importance for the development of personalized medicine | |
| 15) | FINALS WEEK |
| Course Notes / Textbooks: | Öğretim üyesi tarafından hazırlanan ders notları, ppt sunumlar ve alandaki güncel bilimsel yayınlar. |
| References: | Lecture notes prepared by the lecturer, ppt presentations and current scientific publications in the field. |
| Course Learning Outcomes | 1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Program Outcomes | ||||||||||||||||
| 1) The ability to define basic concepts of Cancer Biology and Pharmacology, get information objectively about the related field within the scope of the program | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| 2) Having knowledge about the molecular mechanisms of cancer, learning the process of carcinogenesis at molecular level | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| 3) Learning of pharmacology and anti-cancer drug development, screening and relevant molecular/cellular techniques (cytotoxicity, etc.), get information about the postgraduate regulation related to cancer research and drug development, cooperation and experience share with institutions providing technological support | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| 4) The ability to synthesize, analyze, interpret, interrogate and criticize the relevant information on cancer biology and drug development | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| 5) The ability to use good communication skills and computer technology efficiently in their work | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 6) The ability to convey/present the findings of the research and the results either verbally or in writing | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| 7) The ability to carry out professional and academic studies independently using accumulated knowledge and to work and take responsibility as a team member with other professions working in this field | ||||||||||||||||
| 8) Having a sense of ethical responsibility in research | ||||||||||||||||
| No Effect | 1 Lowest | 2 Average | 3 Highest |
| Program Outcomes | Level of Contribution | |
| 1) | The ability to define basic concepts of Cancer Biology and Pharmacology, get information objectively about the related field within the scope of the program | 3 |
| 2) | Having knowledge about the molecular mechanisms of cancer, learning the process of carcinogenesis at molecular level | 3 |
| 3) | Learning of pharmacology and anti-cancer drug development, screening and relevant molecular/cellular techniques (cytotoxicity, etc.), get information about the postgraduate regulation related to cancer research and drug development, cooperation and experience share with institutions providing technological support | 2 |
| 4) | The ability to synthesize, analyze, interpret, interrogate and criticize the relevant information on cancer biology and drug development | 3 |
| 5) | The ability to use good communication skills and computer technology efficiently in their work | 1 |
| 6) | The ability to convey/present the findings of the research and the results either verbally or in writing | 2 |
| 7) | The ability to carry out professional and academic studies independently using accumulated knowledge and to work and take responsibility as a team member with other professions working in this field | |
| 8) | Having a sense of ethical responsibility in research |
| Semester Requirements | Number of Activities | Level of Contribution |
| Homework Assignments | 1 | % 50 |
| Presentation | 1 | % 50 |
| total | % 100 | |
| PERCENTAGE OF SEMESTER WORK | % 100 | |
| PERCENTAGE OF FINAL WORK | % | |
| total | % 100 | |
| Activities | Number of Activities | Preparation for the Activity | Spent for the Activity Itself | Completing the Activity Requirements | Workload | ||
| Course Hours | 4 | 2 | 2 | 16 | |||
| Study Hours Out of Class | 4 | 0 | 4 | 16 | |||
| Presentations / Seminar | 8 | 4 | 4 | 64 | |||
| Homework Assignments | 6 | 0 | 6 | 36 | |||
| Total Workload | 132 | ||||||